Objectives: It is hypothesized that carcinoma-ex-pleomorphic adenoma (Ca-ex-PA) is malignant from the beginning or is a malignant transformation of a recurrent or a long-standing pleomorphic adenoma (PA). The accumulation of genetic instabilities is suggested to be the main reason for malignant transformation in PA. The aim of this study was to determine the prevalence of BRCA1/2 mutations in PA and Ca-ex-PA.

Materials and Methods: A total of ninety salivary gland tumors (45 Ca ex-PA and 45 PA) were selected. Immunohistochemistry was performed for all samples. Analyses were conducted through SPSS software version 22.0 (SPSS, Inc., Chicago, IL, USA). Chi-square test was used to examine the differences between the variables. Significant level was set at 0.05.

Results: In general, 93.3% of PA samples showed positive staining for BRCA1 (in myoepithelial cells); however, BRCA2 positivity was found in 60% of samples (in myoepithelial cells). Among 45 samples of Ca-ex-PA, 93.3% of showed positivity for BRCA1 and 80% of samples showed positivity for BRCA2. Chi-square test found differences between PAs and Ca-ex-PAs regarding BRCA1/2 mutations in ductal cells and myoepithelial cells (P = 0.007, 0.000), respectively.

Conclusions: The present study found a trend toward the presence of BRCA1/2 mutations in PA and Ca-ex-PA samples. Patients with BRCA1/2 mutation carriers are excellent cases for therapies, such as the poly (ADP) ribose polymerase inhibitor.

Keywords: BRCA1, BRCA2, mutation, neoplasm, salivary glands
suggested that heredity may play a crucial role in its development.\[^{10}\]

BRCA1/2 genes involve in some biological processes expressed in different cells. BRCA1 regulates all phases of the cell cycle and triggers the cell response to DNA damage which blocks cell proliferation and promotes apoptosis; therefore, it stops malignant transformation. In cases of mutation in BRCA1/2 genes, the accumulation of damaged DNA occurs in the replicating cells, resulting in cancer development. In 2%–3% of all breast cancers, BRCA1/2 mutations have been reported.\[^{11}\] Altered expression level of BRCA1 is associated with poor prognosis and shortened survival in breast cancer.\[^{12}\] BRCA2 mutation is also associated with a high risk of prostate cancer and a worse prognosis.\[^{13}\] Salivary glands and breast tissue are composed of tubular acinar exocrine glands; therefore, it can be expected to share similar pathological disorders. There is enough evidence of developing the same types of tumors in both tissues. One of these neoplasms is PA which has been reported in both salivary glands and breasts.\[^{14,15}\] Therefore, there is a need for investigations on the mechanisms associated with tumorigenesis. Immunohistochemistry of BRCA1/2 proteins in tumor cells can be a useful method in patient screening.\[^{16}\]

The aim of this study was to determine the prevalence of BRCA1/2 mutations in PA and CA-ex-PA which has beneficial prognostic factors for patients with examined salivary gland tumors.

**Materials and Methods**

**Patient selection**

As Ca-ex-PA is not a common lesion, only 45 cases were found in the Archive of Pathology Department of Loghman Hakim Hospital, Tehran, Iran, from 2000 to 2016. Therefore, 45 cases of PA were selected to make better match between two tumor types. As the paraffin blocks of the patients were used for this study, the ethical committee of the university declared that there was no need for ethical approval.

**Immunohistochemical Assessment**

First, the formalin-fixed, paraffin-embedded samples were cut for preparing H and E staining to confirm the diagnosis. Then, 5 µm cut sections were deparaffinized, rehydrated, and immersed in pH 6.0 citrate buffer. Heat-induced antigen retrieval was performed for 20 min. Slides were incubated with primary mouse monoclonal anti-BRCA1 antibody (Abcam, ab16780) at 1:90 dilution and primary rabbit polyclonal anti-BRCA2 antibody (Abcam, ab 27976) at 1:80 for 1 h at room temperature, followed by incubation with secondary antibody for 30 min and immunostained with DAB (3, 3'-diaminobenzidin) for 5 min as a chromogen and hematoxylin as counterstain. Breast cancer tissue served as positive control.

**Variable Considerations**

Brown cytoplasmic/nuclear staining was considered to be a positive immunoreactivity for BRCA1, and brown nuclear staining was considered a positive staining for BRCA2. All positive staining were evaluated using a semi-quantitative scoring system for the percentage of positively stained cancer cells as follows: occasional staining but <10% were considered negative, 10%–40% were considered mild, 40%–70% were scored moderate, and >70% were considered intense staining.\[^{17}\]

**Statistical Analyses**

Analyses were conducted through SPSS software version 22.0 (SPSS, Inc., Chicago, IL, USA). Chi-square test was used to examine the differences between the variables. Significant level was set at 0.05. To employ Chi-square test, all the 45 cases of Ca-ex-PA were considered as one group (regardless of histological subtypes).

**Results**

The studied population consisted of ninety samples (45 samples of each lesion; PA or Ca-ex-PA). Thirty samples of PA were female and 15 were male, with a mean age of 56.4 years (range: 23–80 years). Of CA-ex-PA samples, 32 were female and 13 were male, with a mean age of 60.3 years (range: 31–79 years). The parotid gland was the main site affected by PA in thirty cases, followed by minor salivary glands of palate in ten cases, and the remaining five cases affected by submandibular glands. Of the 45 cases of Ca-ex-PA, 38 cases involved the parotid glands, 6 cases palatal salivary glands, and only one case was found in submandibular glands. In general, 93.3% of PA samples showed positive staining for BRCA1 (in myoepithelial cells); however, BRCA2 positivity was found in 60% of samples (in myoepithelial cells) [Figures 1-3]. Among the 45 samples of Ca-ex-PA, 93.3% of showed positivity for BRCA1 and 80% of samples showed positivity for BRCA2. Chi-square test found differences between PAs and Ca-ex-PAs regarding BRCA1/2 mutations in ductal cells and myoepithelial cells (\(P = 0.007, 0.000\)), respectively. Mann–Whitney test showed that there was a significant difference between BRCA1 expression level in myoepithelial cells not in ductal cells in compared groups (\(P = 0.000\)). In addition, there were significant differences between BRCA2 expression levels in both ductal cells (\(P = 0.004\)) and myoepithelial cells (\(P = 0.000\)) in examined groups.
Among the 45 cases of Ca-ex-PA, there were 19 cases of adenocarcinoma not otherwise specified (AdNOS), 12 cases of salivary ductal carcinoma (SDC), 5 cases of epithelial–myoepithelial carcinoma (EMC), 5 cases of myoepithelial carcinoma (MC), 3 cases of adenoid cystic carcinoma (AdCC), and one case of polymorphous low-grade adenocarcinoma (PLGA). Tables 1 and 2 summarize BRCA1/2 staining in PA and Ca-ex-PA samples, respectively. All samples except two AdNOS samples and one SDC sample were positive for BRCA1 mutation in ductal cells [Figures 1-3]. In addition, all samples except four AdNOS samples, three SDC

**Table 1: The BRCA1 and BRCA2 expression levels in different cells of pleomorphic adenoma samples**

| Cell type          | BRCA1 (%) | BRCA2 (%) | P         |
|--------------------|-----------|-----------|-----------|
| Ductal cells       |           |           |           |
| <15                | 16 (76.2) | 0         | 0.000*    |
| ≥15                | 5 (23.8)  | 21 (100)  |           |
| Myoepithelial cells|           |           |           |
| Positive           | 0         | 9 (42.9)  | 0.000*    |
| Negative           | 21 (100)  | 12 (57.1) |           |
| Chondroid cells    |           |           |           |
| Weak               | 20 (95.2) | 1 (4.8)   | 0.000*    |
| Moderate           | 1 (4.8)   | 18 (85.7) |           |
| Strong             | 0         | 2 (9.5)   |           |
| Myxoid cells       |           |           |           |
| Weak               | 8 (38.1)  | 0         | 0.000*    |
| Moderate           | 11 (52.4) | 7 (33.3)  |           |
| Strong             | 2 (9.5)   | 14 (66.7) |           |

**Table 2: The BRCA1 and BRCA2 expression levels in carcinoma-ex-pleomorphic adenoma samples**

| Cancer subtype                              | BRCA1 (%) | BRCA2 (%) |
|---------------------------------------------|-----------|-----------|
| Adenocarcinoma not otherwise specified     |           |           |
| Positive                                   | 16 (76.2) | 0         |
| Negative                                   | 5 (23.8)  | 21 (100)  |
| Salivary duct carcinoma                    |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |
| Epithelial–myoepithelial carcinoma         |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |
| Myoepithelial carcinoma                    |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |
| Adenoid cystic carcinoma                   |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |
| Mucoepidermoid carcinoma                   |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |
| Polymorphous low-grade carcinoma           |           |           |
| Positive                                   | 0         | 9 (42.9)  |
| Negative                                   | 21 (100)  | 12 (57.1) |

**Figure 1:** Higher magnification shows BRCA1 positivity in pleomorphic adenoma sample. Notice nuclear/cytoplasmic positivity in ductal cells, myoepithelial cells, and the cells in the myxoid material

**Figure 2:** High power shows BRCA1 nuclear/cytoplasmic positivity in myoepithelial cells and the cells in the chondroid material in pleomorphic adenoma sample

**Figure 3:** Higher magnification indicates BRCA2 nuclear positivity in myoepithelial cells and the cells in the chondroid material in pleomorphic adenoma samples
samples, and two MC samples were positive for BRCA2 mutation in ductal cells. Figures 4-15 show BRCA1/2 mutations in examined samples.

**Discussion**

According to the morphological and immunohistochemical features, Ca-ex-PAs are classified into two groups. The first group constitutes those with ductal epithelial differentiation, probably derived from ductal luminal cells, including AdNOS, SDC, MEC, and PLGA. The second group comprises those with myoepithelial differentiation, likely derived from the precursor of myoepithelial and ductal cells, such as MC, EMC, and AdCC. Although both luminal and myoepithelial cells may undergo carcinomatous transformation, it is believed that, in most cases, malignancy arises from the luminal structures. Ca-ex-PA arises in a primary or recurrent PA mainly in the parotid gland. A low rate of recurrence and regional metastasis are the clinical features of Ca-ex-PAs. The malignant part of that is mostly a high-grade carcinoma such as SDC or MC.

As there are similarities between the embryogenesis of salivary gland and breast as well as the dual epithelial–myoepithelial cell differentiation in both tissues, it is logical to expect the occurrence of salivary gland-type neoplasm in the breast. Some neoplasms of the breast have similar histological features to salivary gland tumors. In addition, the same genetic abnormalities are found in both salivary gland tumours and breast cancers. For example, a recurrent t (6;9) translocation resulting in the formation of the MYB–NFIB fusion gene can be found in AdCC of both salivary glands and breast. DNA repair deficiencies are described as risk factors in several cancers. Different proteins are involved in repairing the DNA damage. In case of inefficiency of one of these mechanisms, some others promote the DNA repair. BRCA1/2 genes involve in DNA repairing. To the best of our knowledge, this is the first time that BRCA1/2 mutations have been investigated in two salivary gland tumors. In general, the present...
study indicated BRCA1 mutation in 95.6% of PAs and 60% of Ca-ex-PAs. Both luminal and myoepithelial cells showed BRCA1/2 mutations. Komenaka et al. have found BRCA1/2 mutations in 60%–85% of breast...
cancers.[12] According to Madjd et al.'s study, 46% of the breast cancer samples were BRCA1 positive. The authors arrived at the conclusion that BRCA1 protein can be a prognostic marker.[22] Petrucelli et al. have shown BRCA1/2 mutations in 50% of all hereditary breast cancers.[23] Strickland et al. in a study on high-grade serous ovarian cancer found 94.1% positivity of BRCA1 in the samples.[24] Lavie et al. have reported the BRCA1 germline mutation in 20% of uterine serous papillary carcinomas.[25] These findings explain the importance of accurate identification of high-risk cases to increase life expectancy.

Several genomic alterations are associated with progression from PA to Ca-ex-PA including those in pleomorphic adenoma gene 1 (PLAG1), HMGA2, MDM2, TP53, MYC, and epidermal growth factor receptor.[26-28] In addition, the amplification of MDM2, HMGA2, and deletion of 5q23.2q31.2 and 8q22.1q24.1 is an important factor in the transition from PA to Ca-ex-PA.[29] Therefore, molecular subtyping of salivary neoplasms can help in targeted therapies.[30] Chromosomal translocations involving the long arms of chromosomes 8 (8q12), 12 (12q15), and 6 (6p21) have been reported in PAs.[31] Chromosomal translocations of 8q12 usually lead to the activation of the PLAG1;[26] however, rearrangement of the other two genes results in high mobility group (HMG) protein genes, such as HMGIC and HMGIIY.[32] PLAG1 has a dual role, as oncogene and as tumor suppressor. It promotes cellular growth and also inhibits proliferation. In pleomorphic adenoma-like tumor of the breast, PLAG1, activated by the reciprocal chromosomal translocations involving 8q12, is also rearranged and overexpressed in salivary PA. The abnormal expression of PLAG1 may result in a deregulation of PLAG1 target genes involving salivary gland tumorigenesis.[28] PLAG1 overexpression has been detected in PA and in low-grade histopathologic subtypes of Ca-ex-PA, such as MC and EMC.[33] In PA, PLAG1 expression has been demonstrated in both myoepithelial cells and ductal epithelial cells, supporting the hypothesis of a monoclonal origin of PA. Activation of PLAG1 during malignant transformation from PA to Ca-ex-PA is one of the pathways of malignant transformation.[14] HMGA2 is a target gene in both PA and Ca-ex-PA. In PA, it is targeted with translocations involving 12q14-15.[27] Bahrami et al. found PLAG1 abnormality and HMGA2 abnormality in 22.7% and 18.2% of Ca-ex-PA cases, respectively. However, only one case showed abnormality for both PLAG1 and HMGA2.[27] Katabi et al. indicated that 67% of hypocellular myxoid PAs showed PLAG1 or HMGA2 rearrangements; however, only 29% of cellular PAs showed PLAG1 or HMGA2 rearrangements. The authors proposed that cellular PA might represent a discrete genetic subgroup. Besides, EWSR1 gene rearrangement has been shown as a common event in myoepithelial tumors such as salivary gland tumors.[35]

It is believed that p53 mutation is an early event in the progression of PA to Ca-ex-PA. In a previous report, p53 positivity was found in 0%–41% of PAs and 45.2%–75% of Ca-ex-PAs.[8] However, another investigation carried out by DeRoche et al. indicated that p53 expression is not a reliable factor to predict early malignant transformation in PA.[8,36] In addition, p53 and PIK3CA mutations have been identified in acinic cell carcinoma of the breast; nevertheless, the same mutations have not been detected in salivary gland acinic cell carcinoma.[20] It has been suggested that BRCA1/2 and p53 pathways cooperate in breast cancer suppression. In addition, the p53 gene mutation has frequently been reported in breast cancer as
well as other cancers. It is proposed that mutation in both pathways enhances tumor growth.[37]

Overexpression of HER-2/neu protein, a well-known proto-oncogene, was detected in the majority of SDCs of parotid gland associated with a poor prognosis. According to Škalová et al.’s report, HER-2/neu protein was overexpressed in SDC and Ca-ex-PA but not in the benign cells of PA, suggesting the HER-2/neu protein as a useful tool in detecting malignant transformation of PAs.[38]

CONCLUSIONS

PA is the most common benign salivary gland tumor and Ca-ex-PA is a rare, aggressive salivary gland tumor with unknown pathogenesis. Some investigators believe that Ca-ex-PA is a carcinomatous transformation of PA; however, some others propose that it is a malignant tumor from the onset. This study was carried out to clarify the pathogenesis of Ca-ex-PA. The present study found a trend toward the presence of BRCA1/2 mutations in PA and Ca-ex-PA samples. As there are some similarities between salivary gland tissue and breast tissue, it may be logical to arrive at this conclusion that the patients with salivary gland neoplasms have a high risk of BRCA1/2 mutations. Previous studies have shown that the patients with BRCA1/2 mutation carriers are excellent cases for therapies, such as the poly (ADP) ribose polymerase inhibitor.[17] IHC is a low-cost and efficient method,[59] therefore, it can serve as a screening test for detection of BRCA1/2 dysfunction in salivary gland tumor. The knowledge of the spectrum of mutations can provide more efficient protocol for screening and therapeutic strategy. Rarity of Ca-ex-PA limits the number of cases. Further studies with more cases should be done to confirm the results of this study, especially those for rare subgroups.

ACKNOWLEDGMENT

The authors would like to acknowledge the funding from Hamadan University of Medical Sciences.

FINANCIAL SUPPORT AND SPONSORSHIP

This work was supported by Hamadan University of Medical Sciences.

CONFLICTS OF INTEREST

There are no conflicts of interest.

REFERENCES

1. Irani S, Bidari-Zerehpoush F. How useful is the agnor staining method for the diagnosis of salivary gland tumors? Avicenna J Dent Res 2016;8:25275.
2. Shishegar M, Ashraf MJ, Azarpira N, Khademi B, Hashemi B, Ashrafi A, et al. Salivary gland tumors in maxillofacial region: A retrospective study of 130 cases in a Southern Iranian population. Patholog Res Int 2011;2011:934350.
3. Chitturi RT, Veeravarmal V, Nirmal RM, Reddy BV. Myoepithelial cells (MEC) of the salivary glands in health and tumours. J Clin Diagn Res 2015;9:ZE14-8.
4. Lim CM, Hobson C, Kim S, Johnson JT. Clinical outcome of patients with carcinoma ex pleomorphic adenoma of the parotid gland: A comparative study from a single tertiary center. Head Neck 2015;37:543-7.
5. Sakamoto Y, Fujita S, Adachi M, Sakamoto H, Naruse T, Yanamoto S, et al. Carcinoma ex pleomorphic adenoma of the tongue: Difficulty in diagnosis between metastasis of breast cancer and salivary tumor. J Craniofac Surg 2017;28:e182-5.
6. Keerthi R, Raut RP, Vaibhav N, Ghosh A. Carcinoma ex pleomorphic adenoma: Diagnostic dilemma and treatment protocol. Indian J Dent 2014;5:157-60.
7. Mariano FV, Noronha AL, Gondak RO, Altemani AM, de Almeida OP, Kowalski LP, et al. Carcinoma ex pleomorphic adenoma in a Brazilian population: Clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg 2013;42:685-92.
8. Kim JW, Kwon GY, Roh JL, Choi SH, Nam SY, Kim SY, et al. Carcinoma ex pleomorphic adenoma of the salivary glands: Distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation. J Korean Med Sci 2011;26:1277-85.
9. Antony J, Gopalan V, Smith RA, Lam AK. Carcinoma ex pleomorphic adenoma: A comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 2012;6:1-9.
10. Nikolić N, Anićić B, Tepavčević Z, Jezdić Z, Čarkić J, Toljić B, et al. Somatic mutation and polymorphism analysis in pleomorphic adenomas of the salivary glands. J Med Biochem 2013;32:4.
11. Cavanagh H, Rogers KM. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract 2015;13:16.
12. Komenaka IK, Ditkoff BA, Joseph KA, Russo D, Gorroochurn P, Ward M, et al. The Development of Interval Breast Malignancies in Patients with BRCA Mutations. Cancer 2004;100:2079-83.
13. Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015;68:186-93.
14. Omar TA, ElDidi F, Nawar WM. A potential role for sex hormone receptor antagonists in treatment of malignant salivary gland tumours, as compared to breast cancer: A review of literature. Tanta Dent J 2013;10:75-85.
15. Piscuoglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015;67:529-37.
16. Vaz FH, Machado PM, Brandão RD, Laranjeira CT, Esguêño JS, Fernandes AH, et al. Familial breast/ovarian cancer and BRCA1/2 genetic screening: The role of immunohistochemistry as an additional method in the selection of patients. J Histochem Cytochem 2007;55:1105-13.
17. Andisheh-Tadbir A, Dehghani-Nazhvani A, Ashraf MJ, Khademi B, Mirhadi H, Torabi-Ardekani S, et al. MTA1...
expression in benign and malignant salivary gland tumors. Iran J Otorhinolaryngol 2016;28:51-9.
18. Altemani A, Martins MT, Freitas L, Soares F, Araújo NS, Araújo VC, et al. Carcinoma ex pleomorphic adenoma (CXA): Immunoprofile of the cells involved in carcinomatous progression. Histopathology 2005;46:635-41.
19. Luers JC, Wittekindt C, Streppel M. Carcinoma ex pleomorphic adenoma of the parotid gland. Study and implications for diagnostics and therapy. Acta Oncol. 2009;48:132-136.
20. Piscuglio S, Hodi Z, Katabi N, Guerini-Rocco E, Macedo GS, Ng CK, et al. Are acinic cell carcinomas of the breast and salivary glands distinct diseases? Histopathology 2015;67:529-37.
21. Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, et al. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Res Treat 2015;150:81-90.
22. Madjd Z, Karimi A, Molanae S, Asadi-Lari M. BRCA1 protein expression level and CD44(+) Phenotype in breast cancer patients. Cell J 2011;13:155-62.
23. Petruccielli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12:245-59.
24. Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7:13587-98.
25. Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004;92:521-4.
26. Matsuyama A, Hisaoka M, Nagao Y, Hashimoto H. Aberrant PLAG1 expression in pleomorphic adenomas of the salivary gland: A molecular genetic and immunohistochemical study. Virchows Arch 2011;458:583-92.
27. Bahrami A, Perez-Ordonez B, Dalton JD, Weinreb I. An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions. Histopathology 2013;63:250-62.
28. Ochal-Choińska AJ, Osuch-Wójcikiewicz E. Particular aspects in the cytogenetics and molecular biology of salivary gland tumours-Current review of reports. Contemp Oncol (Pozn) 2016;20:281-6.